Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma
Yasushi Iida, Michael Churchman, Robert L. Hollis, Sarah Elizabeth Taylor, Clare Bartos, Ian Croy, William Gentleman, Tzyvia Rye, Rachel Nirsimloo, C. Simon Herrington, Charlie Gourley, Aikou Okamoto, John P. Thomson
This study identifies ARID1A mutation and low CD3+ TIL levels as prognostic markers for relapse in low-stage clear cell ovarian carcinoma.
Gynecologic Oncology · May 27, 2025Peer-reviewedCancer Biology